Advances in covalent kinase inhibitors

Ayah Abdeldayem, Yasir S Raouf, Stefan N Constantinescu, Richard Moriggl, Patrick T Gunning

Overview

Over the past decade, covalent kinase inhibitors (CKI) have seen a resurgence in drug discovery. Covalency affords a unique set of advantages as well as challenges relative to their non-covalent counterpart. After reversible protein target recognition and binding, covalent inhibitors irreversibly modify a proximal nucleophilic residue on the protein via reaction with an electrophile. To date, the acrylamide group remains the predominantly employed electrophile in CKI development, with its incorporation in the majority of clinical candidates and FDA approved covalent therapies. Nonetheless, in recent years considerable efforts have ensued to characterize alternative electrophiles that exhibit irreversible or reversibly covalent binding mechanisms towards cysteine thiols and other amino acids. This review article provides a comprehensive overview of CKIs reported in the literature over a decade period, 2007–2018. Emphasis is placed on the rationale behind warhead choice, optimization approach, and inhibitor design. Current FDA approved CKIs are also highlighted, in addition to a detailed analysis of the common trends and themes observed within the listed data set.

Summary

Covalent Kinase Inhibitors (CKIs) have generated much excitement and gained traction as an effective strategy for small molecule interrogation of the kinome. CKI’s are important therapeutic agents which ideally exhibit rapid target engagement, improved potency and selectivity. Most recently, efforts to fine tune electrophilic reactivity has facilitated improved clinical efficacy and patient outcomes. Due to the ubiquitous role played by kinases in disease, a comprehensive review of CKIs, an increasingly popular drug modality that offers promise of improving kinase-selectivity profiles, would be of great interest to the fields of medicinal chemistry and chemical biology.

Altmetric Statistics

Author Comments

Yasir Raouf
Yasir Raouf
University of Toronto Mississauga
This comprehensive review details the last 10-years of kinase-targeting covalent inhibitors, consolidating all published inhibitors within this period. It provides a focus on electrophilic warhead development, scaffold design, metabolic stability and pharmacodynamics. In addition, to achieve further insight into covalent strategies, the review includes a detailed data analysis section regarding the chemical and physical properties of CKIs. This illuminate the trends which underpin their positive and negative attributes. This analysis may inform and accelerate current and future programs utilizing a covalent approach in drug discovery or chemical biologyYasir Raouf

Resources

Advances in covalent kinase inhibitors
https://pubs.rsc.org/en/content/articlelanding/2020/cs/c9cs00720b#!divAbstract

Advances in covalent kinase inhibitors.

Chem Soc Rev 2020 May 30;49(9):2617-2687. Epub 2020 Mar 30.

Department of Chemical & Physical Sciences, University of Toronto, 3359 Mississauga Road, Mississauga, ON L5L 1C6, Canada.

Over the past decade, covalent kinase inhibitors (CKI) have seen a resurgence in drug discovery. Covalency affords a unique set of advantages as well as challenges relative to their non-covalent counterpart. After reversible protein target recognition and binding, covalent inhibitors irreversibly modify a proximal nucleophilic residue on the protein via reaction with an electrophile. To date, the acrylamide group remains the predominantly employed electrophile in CKI development, with its incorporation in the majority of clinical candidates and FDA approved covalent therapies. Nonetheless, in recent years considerable efforts have ensued to characterize alternative electrophiles that exhibit irreversible or reversibly covalent binding mechanisms towards cysteine thiols and other amino acids. This review article provides a comprehensive overview of CKIs reported in the literature over a decade period, 2007-2018. Emphasis is placed on the rationale behind warhead choice, optimization approach, and inhibitor design. Current FDA approved CKIs are also highlighted, in addition to a detailed analysis of the common trends and themes observed within the listed data set.

Download full-text PDF

Source
http://dx.doi.org/10.1039/c9cs00720bDOI Listing
May 2020
33.383 Impact Factor

Publication Analysis

Top Keywords

covalent kinase
8
fda approved
8
kinase inhibitors
8
alternative electrophiles
4
electrophiles exhibit
4
exhibit irreversible
4
characterize alternative
4
efforts ensued
4
ensued characterize
4
irreversible reversibly
4
covalent binding
4
thiols amino
4
amino acids
4
cysteine thiols
4
mechanisms cysteine
4
considerable efforts
4
binding mechanisms
4
reversibly covalent
4
therapies years
4
electrophile cki
4

Altmetric Statistics

References

(Supplied by CrossRef)

Desborough et al.
Br. J. Haematol. 2017

Vane et al.
Thromb. Res. 2003

Thun et al.
N. Engl. J. Med. 1991

Chen et al.
Lancet 1997

Ridker et al.
N. Engl. J. Med. 2005

Erhlich et al.
Lancet 1913

Langley et al.
J. Physiol. 1901

Langley et al.
J. Physiol. 1905

Ahlquist et al.
Am. J. Physiol. 1948

Lefkowitz et al.
Proc. Natl. Acad. Sci. U. S. A. 1970

Limbird et al.
Mol. Interventions 2004

Similar Publications